HMGA2 and p14Arf: Major roles in cellular senescence of fibroids and therapeutic implications

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 753-761

  Markowski, Dominique Nadine ^a   Helmke, Burkhard Maria ^b   Belge, Gazanfer ^a   Nimzyk, Rolf ^a   Bartnitzke, Sabine ^a   Deichert, Ulrich ^c   Bullerdiek, Jörn ^a,d  

^a UNIVERSITY OF BREMEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Hospital Cuxhaven   (Germany)

^d UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Arf induced senescence; Fibroid cells; HMGA2; Leiomyoma; MDM2 antagonists

Indexed keywords

BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HIGH MOBILITY GROUP A2 PROTEIN; KI 67 ANTIGEN; NUTLIN 3; PROTEIN BAX; PROTEIN MDM2; PROTEIN P53; IMIDAZOLE DERIVATIVE; MDM2 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; SMALL INTERFERING RNA; TUMOR MARKER;

ADULT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL AGING; CELL PROLIFERATION; CELL RENEWAL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEIOMYOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TUMOR CELL; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; UTERUS CANCER;

APOPTOSIS; BETA-GALACTOSIDASE; CELL AGING; CELL LINE, TRANSFORMED; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HUMANS; IMIDAZOLES; LEIOMYOMA; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF; UTERINE NEOPLASMS;

EID: 79956116941     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. DeWaay DJ, Syrop CH, Nygaard IE, Davis WA and Van Voorhis BJ: Natural history of uterine polyps and leiomyomata. Obstet Gynecol 100: 3-7, 2002. (Pubitemid 34722837)
2. Laser J, Lee P and Wei JJ: Cellular senescence in usual type uterine leiomyoma. Fertil Steril 93: 2020-2026, 2010.
3. Peddada SD, Laughlin SK, Miner K, Guyon JP, Haneke K, Vahdat HL, Semelka RC, Kowalik A, Armao D, Davis B and Baird DD: Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci USA 105: 19887-19892, 2008.
4. Arf expression. Cell 135: 227-239, 2008.
5. Arf-TP53-CDKNIA axis: A delicate balance in the growth of uterine leiomyomas. Genes Chromosomes Cancer 49: 661-668, 2010.
6. Hodge JC and Morton CC: Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. Hum Mol Genet 16: Spec No 1: R7-13, 2007.
7. Mooi WJ and Peeper DS: Oncogene-induced cell senescence-halting on the road to cancer. N Engl J Med 355: 1037-1046, 2006. (Pubitemid 44343547)
8. Klemke M, Meyer A, Nezhad MH, Bartnitzke S, Drieschner N, Frentzen C, Schmidt EH, Belge G and Bullerdiek J: Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. Genes Chromosomes Cancer 48: 171-178, 2009.
9. Markowski DN, Bartnitzke S, Beige G, Drieschner N, Helmke BM and Bullerdiek J: Cell culture and senescence in uterine fibroids. Cancer Genet Cytogenet 202: 53-57, 2010.
10. Brown CJ, Lain S, Verma CS, Fersht AR and Lane DP: Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862-873, 2009.
11. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N and Liu EA: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848, 2004.
12. Kurosu T, Wu N, Oshikawa G, Kagechika H and Miura O: Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. Apoptosis 15: 608-620, 2010.
13. Efeyan A, Ortega-Molina A, Velasco-Miguel S, Herranz D, Vassilev LT and Serrano M: Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res 67: 7350-7357, 2007. (Pubitemid 47206565)
14. Stern C, Kazmierczak B, Thode B, Rommel B, Bartnitzke S, Dal Cin P, van de Ven W, Van den Berghe H and Bullerdiek J: Leiomyoma cells with 12q15 aberrations can be transformed in vitro and show a relatively stable karyotype during precrisis period. Cancer Genet Cytogenet 54: 223-228, 1991.
15. Mashal RD, Fejzo ML, Friedman AJ, Mitchner N, Nowak RA, Rein MS, Morton CC and Sklar J: Analysis of androgen receptor DNA reveals the independent clonal origins of uterine leiomyomata and the secondary nature of cytogenetic aberrations in the development of leiomyomata. Genes Chromosomes Cancer 11: 1-6, 1994. (Pubitemid 24273967)
16. Sandberg AA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyoma. Cancer Genet Cytogenet 158: 1-26, 2005.
17. Rogalla P, Rohen C, Hennig Y, Deichen U, Bonk U and Bullerdiek J: Telomere repeat fragment sizes do not limit the growth potential of uterine leiomyomas. Biochem Biophys Res Commun 211: 175-182, 1995.
18. Bonatz G, Frahm SO, Andreas S, Heidorn K, Jonat W and Parwaresch R: Telomere shortening in uterine leiomyomas. Am J Obstet Gynecol 179: 591-596, 1998. (Pubitemid 28447232)
19. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC and Vassilev LT: Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 65: 1918-1924, 2005.
20. Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E, Nagashima M, Takenoshita S, Yokota J and Harris CC: Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 68: 3193-3203, 2008.
21. Secchiero P, Corallini F, Gonelli A, Dell'Eva R, Vitale M, Capitani S, Albini A and Zauli G: Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 100: 61-69, 2007. (Pubitemid 46066774)
22. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC and Vassilev LT: Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103: 1888-1893, 2006.
23. Baek WK, Kim D, Jung N, Yi YW, Kim JM, Cha SD, Bae I and Cho CH: Increased expression of cyclin G1 in leiomyoma compared with normal myometrium. Am J Obstet Gynecol 188: 634-639, 2003. (Pubitemid 36332426)
24. Martel KM, Ko AC, Christman GM and Stribley JM: Apoptosis in human uterine leiomyomas. Semin Reprod Med 22: 91-103, 2004.
25. Wu X, Blanck A, Olovsson M, Henriksen R and Lindblom B: Expression of Bcl-2, Bcl-x, Mcl-1), Bax and Bak in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause. J Steroid Biochem Mol Biol 80: 77-83, 2002. (Pubitemid 34178413)